drugset / Trial / NCT07594522

A Study of Ivonescimab in People With Non-Small Cell Lung Cancer

NCT07594522

Phase 1/2 Recruiting 36 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The researchers are doing this study to find out whether ivonescimab after receiving standard stereotactic body radiotherapy (SBRT) is an effective treatment in people with Non-Small Cell Lung Cancer (NSCLC).

Timeline

Start
2026-05-12
Primary completion
2028-05-12
Completion
2028-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivonescimab Monoclonal antibody Intravenous